According to a new market report published by Transparency Market Research “Kaposi Sarcoma Market: (Treatment Type: Chemotherapy, Immunotherapy, and Highly Active Anti-retroviral Therapy (HAART); Distribution Channel: Hospitals, Cancer Research Institutes, Multispecialty Clinics, and Ambulatory Surgical Centers) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016–2024,” the global Kaposi sarcoma market was valued at US$ 118.5 Mn in 2015 and is estimated to reach US$ 143.2 Mn by 2024 at a CAGR of 2.2% from 2016 to 2024.

The prevalence of Kaposi sarcoma (KS) has increased since the emergence of HIV/AIDS, which is driving the market for its treatment. Its prevalence follows geographic and ethnic distribution, and hence its incidence and prevalence is high in African regions. Geographically, the market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Download exclusive Brochure of this report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3354

North America contributed to the major share in the Kaposi sarcoma market in 2015 due to the presence of major market players and increasing cost of drugs. The growth of the market is also driven by the easy availability of drugs and high diagnosis rate of the malignancy. The incidence of KS in the region is comparatively low, and less than 10% of the population is considered to be affected by Kaposi sarcoma. Further, around 95% of AIDS-related KS cases have been diagnosed in homosexual or bisexual men in the U.S. The incidence of organ transplant-related KS was around 0.5% among the recipients. According to Globocan, the incidence of KS in the U.S. was 0.1% of the total cancer incidence in 2012.The commonly used mode of treatment is highly active antiretroviral therapy (HAART) followed by chemotherapy. The most common chemotherapy drugs employed for the treatment include liposomal anthracyclines. However, North America has been witnessing a shortage in the drug supply needed for the treatment of KS, leading to a widening demand-supply gap which would have a negative impact on the market.

Europe was the second largest market for Kaposi sarcoma treatment in 2015, due to the increasing prevalence of HIV/AIDS associated KS and the classic form of KS prevalent in certain regions of Europe. According to Globocan, the incidence of KS was 0.1% of the total cancer incidence in Greece, Ukraine, Switzerland, and Spain; and 0.2% in Italy and Portugal in 2012. The highest incidence of KS was observed in two Mediterranean Italian islands, Sardinia and Sicily. Prevalence of KS is high in Southern Europe, attributed to a combination of classic KS in certain Mediterranean regions and significant growth of HIV/AIDS related KS in certain countries. Stringent drug approval regulations, and high cost of treatment are known to have a negative impact on the growth of the market.

View exclusive Global strategic Business report:
http://www.transparencymarketresearch.com/kaposis-sarcoma-market.html

Middle East and Africa is expected to expand at the highest CAGR during the forecast period, 2016 to 2024. Incidence and prevalence of KS in Eastern Africa is high as compared to Northern Africa, consistent with the geographic variations of the HIV/AIDS epidemic. According to Globocan (2012), incidence of KS in Eastern Africa was around 10.2% of the total cancer incidence in the region, while it was 0.1% in Northern Africa. The prevalence of KS in Eastern Africa was 8.7% of the total cancer prevalence in 2012, much higher than that observed in Northern Africa at 0.1%.The incidence of KS in Africa is also known to be affected by certain genetic, hormonal, and geographic factors. Despite the high incidence of endemic KS and HIV/AIDS associated KS, the lack of awareness among people, late presentation of the disease, high cost of treatment, and unavailability of treatment are few of the factors which would impede the market growth in the Middle East and Africa market. Hence efforts are being made to increase awareness among people, for which governments in Africa and other organizations have been taking initiatives.

Asia Pacific and Latin America accounted for negligible share of the global Kaposi sarcoma market, owing to very low incidence and prevalence of AIDS associated KS in these regions. However, China and Brazil are lucrative markets due to the prevalence of other forms of KS. For instance, classic form of KS is endemic in certain regions of China such as Xinjiang.

Key players operating in the global Kaposi sarcoma market include Bristol Myers Squibb, Eli Lilly and Co., Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough Corporation (Merck & Co., Inc.).

The Global Kaposi Sarcoma market has been segmented as follows:

Kaposi Sarcoma Market, By Type of Treatment

Chemotherapy
Liposomal Anthracyclines
Alkaloids
Immunotherapy
HAART

Kaposi Sarcoma Market, By Distribution Channel

Hospitals
Cancer Research Institutes
Multispecialty Clinics
Ambulatory Surgical Centers
?

Kaposi Sarcoma Market, by Geography

North America
U.S.
Canada

Europe
U.K.
Germany
Rest of Europe

Asia Pacific
China
Japan
India
Australia
Rest of Asia Pacific

Latin America
Brazil
Mexico
Rest of Latin America

Middle East and Africa
U.A.E.
South African Republic
Rest of Middle East and Africa